Comparative Pharmacology
Head-to-head clinical analysis: CODEINE ASPIRIN APAP FORMULA NO 2 versus QOLIANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CODEINE ASPIRIN APAP FORMULA NO 2 versus QOLIANA.
CODEINE, ASPIRIN, APAP FORMULA NO. 2 vs QOLIANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is a prodrug that is metabolized to morphine, which acts as an agonist at mu-opioid receptors in the central nervous system, producing analgesia. Aspirin irreversibly inhibits cyclooxygenase-1 and -2, reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects. Acetaminophen (APAP) inhibits cyclooxygenase centrally, with weak peripheral activity, producing analgesia and antipyresis.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
1 to 2 tablets orally every 4 to 6 hours as needed for pain; maximum 12 tablets per day. Each tablet contains codeine 30 mg, aspirin 325 mg, and acetaminophen 325 mg.
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
None Documented
None Documented
Codeine: 2.5-4 hours. Aspirin (as salicylate): 2-3 hours (low dose), up to 15-30 hours (high dose due to saturable metabolism). Acetaminophen: 2-3 hours (therapeutic doses), prolonged in overdose or hepatic impairment.
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Codeine: Renal 90% (10% unchanged, 80% as conjugates). Aspirin: Renal 80-100% (dose-dependent, as salicylate and metabolites). Acetaminophen (APAP): Predominantly renal (90-100% as conjugates, <5% unchanged).
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Category D/X
Category C
Opioid Agonist
Opioid Agonist